Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? (2016)
Source: Atherosclerosis. Unidade: FM
Subjects: MUTAÇÃO GENÉTICA, LIPÍDEOS, ANTICORPOS MONOCLONAIS, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BANERJEE, Yajnavalka et al. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?. Atherosclerosis, v. 248, n. 1, p. 62-75, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2016.02.018. Acesso em: 16 out. 2024.APA
Banerjee, Y., Santos, R. D., Al-Rasadi, K., & Rizzo, M. (2016). Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? Atherosclerosis, 248( 1), 62-75. doi:10.1016/j.atherosclerosis.2016.02.018NLM
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018Vancouver
Banerjee Y, Santos RD, Al-Rasadi K, Rizzo M. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? [Internet]. Atherosclerosis. 2016 ; 248( 1): 62-75.[citado 2024 out. 16 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2016.02.018
